Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 (GlobeNewswire) - Oct 22, 2023 - P1 | N=160 | NCT03748186 | Sponsor: Sutro Biopharma, Inc | "Sutro Biopharma, Inc...announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with endometrial cancer...Luvelta demonstrated encouraging preliminary anti-tumor activity in patients with FolRα-expressing endometrial cancer; Consistent with previous reported luvelta safety results, the most common adverse event was neutropenia; no new safety signals were observed"
P1 data • Endometrial Cancer
|